Genitourinary Drugs

Global Market Trajectory & Analytics

MCP16424

EXECUTIVE ENGAGEMENTS

POOL

2182
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

393
Interactions with Platform & by Email

PARTICIPANTS

63
Unique # Participated

VALIDATIONS

19
Responses Validated*

COMPANIES

42
Responses Validated*
* Login for a full stack data experience

DATE

APR 2021

TABLES

135

PAGES

207

EDITION

9

PRICE

USD 4950

CODE

MCP16424


COMPETITIVE METRICS

COMPANY

D S N T

% *

Allergan PLC

Astellas Pharma, Inc.

Bayer AG

CO ORD-MED

Daiichi Sankyo Co., Ltd.

ERBAGIL srl

Genmed Group Limited

GlaxoSmithKline PLC

Kynerion S.r.l.

Otsuka Pharmaceutical Co., Ltd.

View More...

SUBMIT
Note: Best viewed in Landscape Mode
  

HIGHLIGHTS & REPORT INDEX

Amid the COVID-19 crisis, the global market for Genitourinary Drugs estimated at US$28.2 Billion in the year 2020, is projected to reach a revised size of US$30.2 Billion by 2027, growing at a CAGR of 1% over the analysis period 2020-2027. Urologicals, one of the segments analyzed in the report, is projected to record a 1.3% CAGR and reach US$6.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Hormonal Therapy Drugs segment is readjusted to a revised 1.1% CAGR for the next 7-year period.
The Genitourinary Drugs market in the U.S. is estimated at US$8.3 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$5.3 Billion by the year 2027 trailing a CAGR of 0.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.1% and 0.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 1.1% CAGR.
In the global Gynecological products segment, USA, Canada, Japan, China and Europe will drive the 1.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$862.3 Million in the year 2020 will reach a projected size of US$941.6 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$3.4 Billion by the year 2027.

SELECT PLAYERS

Allergan PLC; Astellas Pharma, Inc.; Bayer AG; Daiichi Sankyo Co., Ltd.; GlaxoSmithKline PLC; Otsuka Pharmaceutical Co., Ltd.; Pfizer, Inc.; Sanofi SA

SEGMENTS

» Indication (Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia, Other Indications) » Product (Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives, Other Products)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Genitourinary Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Genitourinary Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Genitourinary Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
World Current & Future Analysis for Urologicals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Urologicals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Urologicals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Hormonal Therapy Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Hormonal Therapy Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Hormonal Therapy Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Gynecological products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Gynecological products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Gynecological products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Anti-infectives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Anti-infectives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Anti-infectives by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Ovarian Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Ovarian Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Ovarian Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Bladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Bladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Bladder Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Cervical Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Cervical Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Cervical Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Renal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Renal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Renal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Erectile Dysfunction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Erectile Dysfunction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Erectile Dysfunction by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Urinary Tract Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Urinary Tract Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Urinary Tract Infections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Urinary Incontinence & Overactive Bladder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Urinary Incontinence & Overactive Bladder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Urinary Incontinence & Overactive Bladder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Sexually Transmitted Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Sexually Transmitted Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Sexually Transmitted Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Benign Prostatic Hyperplasia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Benign Prostatic Hyperplasia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Benign Prostatic Hyperplasia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
UNITED STATES
USA Current & Future Analysis for Genitourinary Drugs by Product - Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Genitourinary Drugs by Product - Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Genitourinary Drugs by Product - Percentage Breakdown of Value Sales for Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives and Other Products for the Years 2012, 2020 & 2027
USA Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and Other Indications for the Years 2012, 2020 & 2027
CANADA
Canada Current & Future Analysis for Genitourinary Drugs by Product - Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Genitourinary Drugs by Product - Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Genitourinary Drugs by Product - Percentage Breakdown of Value Sales for Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives and Other Products for the Years 2012, 2020 & 2027
Canada Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and Other Indications for the Years 2012, 2020 & 2027
JAPAN
Japan Current & Future Analysis for Genitourinary Drugs by Product - Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Genitourinary Drugs by Product - Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Genitourinary Drugs by Product - Percentage Breakdown of Value Sales for Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives and Other Products for the Years 2012, 2020 & 2027
Japan Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and Other Indications for the Years 2012, 2020 & 2027
CHINA
China Current & Future Analysis for Genitourinary Drugs by Product - Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Genitourinary Drugs by Product - Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Genitourinary Drugs by Product - Percentage Breakdown of Value Sales for Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives and Other Products for the Years 2012, 2020 & 2027
China Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and Other Indications for the Years 2012, 2020 & 2027
EUROPE
Europe Current & Future Analysis for Genitourinary Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Europe Historic Review for Genitourinary Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Genitourinary Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
Europe Current & Future Analysis for Genitourinary Drugs by Product - Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Genitourinary Drugs by Product - Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Genitourinary Drugs by Product - Percentage Breakdown of Value Sales for Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives and Other Products for the Years 2012, 2020 & 2027
Europe Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and Other Indications for the Years 2012, 2020 & 2027
FRANCE
France Current & Future Analysis for Genitourinary Drugs by Product - Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Genitourinary Drugs by Product - Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Genitourinary Drugs by Product - Percentage Breakdown of Value Sales for Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives and Other Products for the Years 2012, 2020 & 2027
France Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and Other Indications for the Years 2012, 2020 & 2027
GERMANY
Germany Current & Future Analysis for Genitourinary Drugs by Product - Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Genitourinary Drugs by Product - Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Genitourinary Drugs by Product - Percentage Breakdown of Value Sales for Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives and Other Products for the Years 2012, 2020 & 2027
Germany Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and Other Indications for the Years 2012, 2020 & 2027
ITALY
Italy Current & Future Analysis for Genitourinary Drugs by Product - Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Genitourinary Drugs by Product - Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Genitourinary Drugs by Product - Percentage Breakdown of Value Sales for Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives and Other Products for the Years 2012, 2020 & 2027
Italy Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and Other Indications for the Years 2012, 2020 & 2027
UNITED KINGDOM
UK Current & Future Analysis for Genitourinary Drugs by Product - Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Genitourinary Drugs by Product - Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Genitourinary Drugs by Product - Percentage Breakdown of Value Sales for Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives and Other Products for the Years 2012, 2020 & 2027
UK Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and Other Indications for the Years 2012, 2020 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for Genitourinary Drugs by Product - Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Genitourinary Drugs by Product - Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Genitourinary Drugs by Product - Percentage Breakdown of Value Sales for Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives and Other Products for the Years 2012, 2020 & 2027
Rest of Europe Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and Other Indications for the Years 2012, 2020 & 2027
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Genitourinary Drugs by Product - Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Genitourinary Drugs by Product - Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Genitourinary Drugs by Product - Percentage Breakdown of Value Sales for Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives and Other Products for the Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and Other Indications for the Years 2012, 2020 & 2027
REST OF WORLD
Rest of World Current & Future Analysis for Genitourinary Drugs by Product - Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Genitourinary Drugs by Product - Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Genitourinary Drugs by Product - Percentage Breakdown of Value Sales for Urologicals, Hormonal Therapy Drugs, Gynecological products, Anti-infectives and Other Products for the Years 2012, 2020 & 2027
Rest of World Current & Future Analysis for Genitourinary Drugs by Indication - Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Genitourinary Drugs by Indication - Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Genitourinary Drugs by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and Other Indications for the Years 2012, 2020 & 2027
Total Companies Profiled: 42

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com